Want to see GB:ANIC full AI Analyst Report?
Top Page
Agronomics
(LSE:ANIC)
Select Model
Select Model
Rating:44Neutral
Price Target:
5.50 p
▲(5.77% Upside)
Action:Reiterated
Date:01/04/26
The score is weighed down primarily by weak financial performance (recent losses and persistently negative cash flow), with technicals also bearish (price below key moving averages and negative MACD). Valuation is additionally constrained by a negative P/E driven by losses and no dividend data to offset risk; the main positive is the debt-free balance sheet, though equity has been eroding.
Positive Factors
Debt-free balance sheet
Zero reported debt and a meaningful equity base give Agronomics durable financial flexibility to fund follow-on investments, ride sector cycles, and avoid leverage-driven distress. This lowers insolvency risk and supports the firm’s ability to hold illiquid private positions until exits occur.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow means the company is not self-funding and relies on external capital to sustain operations and back investments. Over months this raises dilution and timing risk, constraining the firm’s ability to hold assets to maturity and fund follow-ons.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt and a meaningful equity base give Agronomics durable financial flexibility to fund follow-on investments, ride sector cycles, and avoid leverage-driven distress. This lowers insolvency risk and supports the firm’s ability to hold illiquid private positions until exits occur.
Read all positive factors
Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£60.78M
Dividend YieldN/A
Average Volume (3M)2.60M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS Growth5.88%
CountryUK
EmployeesN/A
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,083,381,100
10 Day Avg. Volume2,299,252
30 Day Avg. Volume2,599,051
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)-5.97
P/FCF Ratio-63.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£13.30Price Target Upside155.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Agronomics Business Overview & Revenue Model
Company Description
Agronomics Limited functions as a dedicated investment firm, primarily allocating capital across various financial instruments, including funds, equities, and equity-linked products. Its portfolio spans both publicly traded and privately held comp...
How the Company Makes Money
Agronomics primarily makes money through investment returns on its portfolio rather than operating revenue from selling goods or services. Its key economic drivers are: (1) Realised gains on exits: profits generated when Agronomics sells equity st...
Agronomics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -11.92M | -11.92M | -8.34M | 29.70M | 440.32K | 10.67M |
| Gross Profit | -11.92M | -11.92M | -8.34M | 29.70M | 440.32K | 10.67M |
| EBITDA | -10.05M | -32.75M | 0.00 | 24.57M | 1.50M | 2.46M |
| Net Income | -16.18M | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
Balance Sheet | ||||||
| Total Assets | 140.21M | 124.67M | 157.44M | 170.20M | 146.40M | 101.65M |
| Cash, Cash Equivalents and Short-Term Investments | 2.15M | 124.62M | 12.24M | 169.87M | 146.30M | 101.21M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 234.67K | 147.60K | 166.17K | 1.95M | 2.49M | 1.62M |
| Stockholders Equity | 139.97M | 124.52M | 157.27M | 168.26M | 143.91M | 100.03M |
Cash Flow | ||||||
| Free Cash Flow | -1.24M | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Operating Cash Flow | -1.24M | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
| Investing Cash Flow | 2.28M | 1.59M | 892.00K | 10.02M | -20.02M | -11.21M |
| Financing Cash Flow | 0.00 | 1.71K | 1.68K | 1.01M | 31.25M | 71.82M |
Agronomics Technical Analysis
Neutral
5.20
Price Trends
5.81
Negative
6.25
Negative
6.45
Negative
Market Momentum
>-0.01
Negative
59.41
Neutral
75.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANIC, the sentiment is Neutral. The current price of 5.2 is below the 20-day moving average (MA) of 5.32, below the 50-day MA of 5.81, and below the 200-day MA of 6.45, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.41 is Neutral, neither overbought nor oversold. The STOCH value of 75.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:ANIC.
Agronomics Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £132.74M | 10.36 | 11.90% | 9.26% | -22.86% | -56.06% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
65 Neutral | £1.04B | 8.93 | 9.21% | ― | -78.12% | 30945.45% | |
61 Neutral | £550.38M | 8.34 | 7.16% | ― | -35.12% | ― | |
52 Neutral | £111.68M | -13.05 | -4.78% | 3.67% | -2.25% | -350.00% | |
44 Neutral | £60.78M | -3.48 | -12.24% | ― | ― | 5.88% | |
42 Neutral | £14.96M | -535.00 | -0.14% | ― | 16.98% | 99.21% |
* Financial Sector Average
GB:ANIC
Agronomics
5.60
-2.30
-29.11%
GB:GROW
Molten Ventures
647.50
282.10
77.20%
GB:IPX
Impax Asset Management
115.00
-56.46
-32.93%
GB:IPO
IP Group plc
68.60
11.60
20.35%
GB:MERC
Mercia Asset Management
27.00
-5.00
-15.63%
GB:EMVC
NetScientific
54.00
2.00
3.85%
Agronomics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Agronomics Chair Jim Mellon Lifts Stake and Tightens Ties With BlueNalu
Positive
Jul 14, 2026
Agronomics has disclosed that executive chair Jim Mellon purchased 27,490,407 Agronomics ordinary shares from portfolio company BlueNalu for US$2 million, alongside previously unreported market purchases of 6,050,000 shares in March, lifting his t...
Business Operations and StrategyM&A Transactions
Tropic Biosciences buys Rahan Meristem to build integrated banana genetics leader
Positive
Jun 25, 2026
Agronomics’ portfolio company Tropic Biosciences has acquired banana propagation specialist Rahan Meristem for $20 million, gaining a network of facilities across Latin America, Asia and the Middle East capable of producing more than 30 mill...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Agronomics Portfolio Firm Bond Pet Foods Wins FDA Nod for Novel Fermented Pet Protein
Positive
Jun 4, 2026
Agronomics said portfolio company Bond Pet Foods has received a US FDA Center for Veterinary Medicine Letter of No Objection for its Lamb Protein Yeast ingredient for use in adult dog food. Developed with Hill’s Pet Nutrition, the precision-...
Business Operations and Strategy
Agronomics Portfolio Firm HydGene Joins Greentown Go Make 2026 Decarbonisation Cohort
Positive
Jun 4, 2026
Agronomics has highlighted that portfolio company HydGene Renewables, a climate-tech firm developing modular biological systems to produce low-carbon hydrogen and industrial chemicals from waste biomass, has been chosen for Greentown Go Make 2026....
Business Operations and StrategyPrivate Placements and Financing
Agronomics boosts SuperMeat stake with premium-funded Series A-4 investment
Positive
May 12, 2026
Agronomics has led a US$6 million initial closing of SuperMeat’s targeted US$10 million Series A-4 round, contributing US$5 million via the issue of 26,805,903 new shares at a significant premium to its recent market price, while an affiliat...
Business Operations and StrategyPrivate Placements and Financing
Agronomics’ Meatly Raises £10.4m to Build Europe’s Largest Cultivated Pet Food Plant
Positive
May 7, 2026
Agronomics’ portfolio company Good Dog Food, trading as Meatly, has closed a £10.4 million Series A round led by climate and consumer-focused investors, lifting its total funding to £17.5 million. Meatly, which develops cultivated ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.